This study aimed to characterize the clinical features and the related cerebral glucose metabolism pattern of cognitive impairments in Parkinson's disease (PD) with positron emission tomography (PET) imaging. We recruited 168 PD patients and 100 age-matched healthy controls of similar education and gender distribution. 
Cognitive impairment in PD is commonly characterized by predominant frontal/executive deficits, while impairments of memory, language, and visuospatial functions are less frequently reported (Foltynie, Brayne, Robbins, & Barker, 2004) . However, more recent reports implicate impairment in variable cognitive domains. This inconsistency in the literature may emanate from the variation in the assessment tools used. For example, earlier studies on cognitive impairment in PD used the Diagnostic and Statistical Manual of Mental Disorders, which focuses more on memory function than other cognitive subdomains. In more recent years, the Movement Disorder Society (MDS) Task Force published criteria for both PD-D and PD-MCI with a comprehensive neuropsychological test battery covering all cognitive subdomains simultaneously to allow more accurate studies (Emre et al., 2007; Litvan et al., 2011) . However, studies on the clinical profiles, of cognitive impairment in PD in the Chinese population are limited, and the results of those using a comprehensive neuropsychological test battery are substantially inconsistent Yu et al., 2012) .
The neurobiological basis of the clinically heterogeneous cognitive deficits in PD remains controversial. Functional neuroimaging may prove useful to explore the underlying mechanisms and provide potentially objective biomarkers. Previously, we reported on regional cerebral glucose metabolism differences between PD patients with different cognitive status, particularly PD-D and PD-MCI (Tang et al., 2016) . However, the more detailed exploration of cerebral metabolism changes relating to performance in the different cognitive domains has yet to be elucidated. We therefore aimed to further investigate the characteristics of cognitive impairment in PD patients across the major cognitive domains, and explore the associated cerebral glucose metabolism with 
| SUBJECTS AND METHODS

| Subjects
A cross-sectional study was conducted in 168 patients diagnosed as idiopathic PD according to the UK Brain Bank criteria (Hughes, Daniel, Kilford, & Lees, 1992) in Huashan Hospital between March 2012 and March 2015. A total of 100 healthy controls with similar age, education, and gender distribution as the PD patients were recruited to obtain normative data. None of the healthy controls had a past history of cognitive impairment, psychiatric illness, central nervous system disease, or head injury. All participants provided written informed consent in accordance with the Declaration of Helsinki. The study was approved by the Human Studies Institutional Review Board, Huashan Hospital, Fudan University.
| Motor assessment
Motor status in PD patients was assessed using the Hoehn and Yahr scale and the motor section of the unified Parkinson's disease rating scale (UPDRS-III; Fahn, Marsonden, Calne, & Goldstein, 1987) in the "OFF" state, which was defined as being off anti-parkinsonian medications for at least 12 hr.
| Cognition assessment
Global cognitive function was evaluated using the Mini Mental State Examination (MMSE). According to the MDS diagnostic criteria for PD-MCI (Litvan et al., 2011) , different cognitive domains (executive function, attention, memory, visuospatial function, and language) were evaluated using a battery of neuropsychological tests. Executive functions were assessed with the Stroop Color-Word Test part C (Steinberg, Bieliauskas, Smith, & Ivnik, 2005) and Trail Making Test part B (TMT-B) (Zhao et al., 2013) ; attention was assessed with Trail Making Test part A (TMT-A) (Zhao et al., 2013) and the Symbol Digit Modalities Test (SDMT) (Sheridan et al., 2006) ; memory function was assessed using the Rey Auditory Verbal Learning Test (AVLT) (Guo, Zhao, Chen, Ding, & Hong, 2009) (Caffarra et al., 2002) ; language ability was assessed with Boston Naming Test (BNT) and Verbal Fluency Test (VFT) (Lucas et al., 2005) .
Cognitive assessment was performed with patients taking their usual anti-parkinsonian medications (i.e., in the ON condition) to conform to current protocols in our clinical research studies. Individual neuropsychological test scores were transformed into Z-scores using the mean and standard deviation of the control sample according to the following formula: (test score − median score from control sample)/standard deviation from control sample. In addition, the Z-score for each cognition domain was the average of the Z-scores of the two tests assessing the same domain.
| Determination of cognitive status
The clinical diagnostic criteria for dementia associated with PD were applied to diagnose dementia in this study (Emre et al., 2007) . MCI was diagnosed according to the Level II recommendations of the MDS Task Force 2012 whereby, deficits should be present in at least two tests, either within one single cognitive domain or across different domains (Emre et al., 2007; Litvan et al., 2012) . Two SDs below the norm was considered abnormal in each test. Values used to determine test score deviations in PD patients were taken from the sample of 100 age-and education-matched healthy control subjects. Patients not fulfilling criteria for MCI or dementia were considered to have normal cognition. (Liu et al., 2018; Ge et al., 2015; Zuo et al., 2013 
| PET imaging and data analysis
| RESULTS
The demographic profiles and clinical information for the 168 PD patients and 100 healthy controls are provided in Table 1 . No significant differences were identified between the two groups.
| Cognitive profile in PD patients and healthy controls
An overview of neuropsychological results for PD patients and controls is provided in Table 2 . Although the global cognitive function (MMSE) did not reveal any difference between the two groups, PD patients had significantly poorer scores on nearly all individual neuropsychological tests (Table 2 ). The highest percentages of PD patients with impairment (i.e., >2 SDs below control mean) on the individual neuropsychological tests were for TMT-B (20.2%) and TMT-A (19.6%). The lowest percentages with impairment were present with FDG uptake were found mainly in putamen, frontal lobe, and temporal lobe (Table 5 and Figure 1 ). We also highlighted the clusters that sur- (Caviness et al., 2007; Muslimovic, Post, Speelman, & Schmand, 2005; Wang et al., 2015) , the majority of our PD-MCI patients had multipledomain deficits (94.9%), similar to the studies using the MDS Task Force criteria (Goldman, Weis, Stebbins, Bernard, & Goetz, 2012; Wood et al., 2016) . The relatively high prevalence and predominantly multiple-domain, impairment of PD-MCI in our study compared to other reports, might be explained by use of the very sensitive level II diagnostic criteria of the MDS Task Force (Litvan et al., 2012) , which was intended to provide more reliable characterization of widespread cognitive dysfunction.
In this study, PD patients had significantly poorer scores than controls on almost all individual neuropsychological tests administered, suggesting a more widespread nature of cognitive impairment in PD (Weintraub et al., 2015) . Our data suggests that PD, PD-MCI, and PD-D patients all have a similar impairment pattern which is most prominent in executive function and attention, followed by deficits in memory and visuospatial abilities, and least impairments in language . However, the neuropathophysiologic mechanisms reduced metabolism in frontal and parietal association areas and increased metabolism in cerebellum and dentate nuclei (Huang et al., 2007) . Our previous work suggested that the hypometabolism was predominantly located in the frontal and temporal cortices in Chinese PD-MCI patients compared with PD-NC patients (Tang et al., 2016) .
In PD-D patients, the hypometabolism in the posterior cortical areas was greater than in PD-MCI patients, suggesting an association between posterior cortical hypometabolism and more severe cognitive impairment (Tang et al., 2016) . However, the association of impaired cerebral metabolism with individual cognitive domain function has not previously been examined in detail. In this study, the Zscores of executive function, attention, memory, and visuospatial function domains correlated positively with metabolism in posterior temporo-parieto-occipital cortex, with some topographical overlap (precuneus, inferior parietal lobule, and superior temporal gyrus). Thus the lower the Z-scores, indicating greater cognitive impairment, the lower the metabolism in posterior temporo-parieto-occipital cortex.
The reduced posterior temporo-parieto-occipital cortex metabolism in the cognitively impaired PD patients likely reflects changes in regional metabolism and neurotransmitter function. The posterior key node of the so-called default mode network (DMN) expresses hyperactivity of interlinked regions during wakeful rest (Buckner, Andrews-Hanna, & Schacter, 2008; Raichle, 2015) , and it plays a crucial role in cognitive processing both in normal aging and neurodegenerative disorders (Agosta et al., 2012; Sambataro et al., 2010) .
In PD, the DMN has been shown to be abnormally modulated (Boord, Madhyastha, Askren, & Grabowski, 2017) and the metabolic decrease in one or more nodes of this network might impede neural resource reallocation for normal task performance (Binder et al., 1999) . In addition, the posterior cortical metabolism changes we temporo-parieto-occipital regions in PD patients (Klein et al., 2010) .
On the basis of these observations of impaired cholinergic function, in combination with our present observations of impaired metabolic function in the same territories, we speculate that cholinergic denervation in posterior association areas may play an important role in the cognitive impairments of PD. We also found that paracentral gyrus and putamen metabolism was negatively correlated with the Z-scores of the cognitive domains.
The lower of the Z-scores (indicating more severe cognitive deficit), the higher of the metabolism in the paracentral gyrus and putamen. In previous studies, hypermetabolism in putamen contributed to a PDrelated pattern (Eidelberg et al., 1994; Ma, Tang, Spetsieris, Dhawan, & Eidelberg, 2007; Wu et al., 2013) , correlating with motor deficiency.
In our previous study, we reported a significant correlation between subdomains of cognitive impairment and motor dysfunction, suggesting shared neurochemical pathways (Wang et al., 2017) . In a previous study, PD-D patients exhibit greater dopamine depletion than nondemented patients (Emre, 2003) . Therefore, it is still necessary to explore unique roles played by dopaminergic deficiency in the cognitive decline using specific radioligands. Work is underway to examine some patients included in this study who were also scanned with dopamine transporter PET imaging.
We found no correlation of (Ci et al., 2016) . In PD patients, structural gray matter changes in temporal, frontal, and cerebellar areas correlate with semantic fluency rather than phonemic fluency scores (Pereira et al., 2009 ). In contrast, striatal volume is associated with phonemic verbal fluency (Ellfolk et al., 2014) . However, in this study we could not confirm a clear relationship between language function and cerebral 18 F-FDG metabolisms in PD. These negative findings may be due to the Boston naming and semantic fluency tests assessing only a limited aspect of the complex and subtle functions of language (Poeppel, 2014) . Therefore, they may not be sensitive enough to reveal any true, albeit subtle, metabolic reduction in a localized node (Klein et al., 2010) . In addition, relative preservation of the language domain is a common finding in studies of cognitive function in PD Wood et al., 2016) .
We want to emphasize that correlations detected between cognitive measures and regional glucose metabolism in this study are inde- 
| LIMITATIONS
There are several limitations in our study. First, inclusion of participants in the healthy control group was based mainly on self-report of medical history rather than medical records, so it's possible that some may have been included inappropriately. However, it is pertinent that none of the controls demonstrated cognitive impairment (e.g., MCI) on detailed assessment. Second, FDG PET scans were acquired in the static mode over 10 min which was selected to be consistent with the imaging protocol used in our previous publications (Ge et al., 2015; Wu et al., 2013) . It has been known that the concentration data provided by this static imaging method is linearly related to brain glucose metabolism (Carson, 1991) . Third, the activated cerebral regions identified in our study are based on the PET metabolism-cognition correlations, and so are limited in elucidating the exact neural networks and specific neurotransmitters associated with cognitive impairment in PD. Future PET studies with specific radioligands, along with autopsy and animal studies may help to provide more specific information in this regard. Fourth, although all the cognitive tests were performed in patients taking their usual daily medications, some unwanted variance in cognitive results might also exist due to the ON/OFF fluctuations.
| CONCLUSION
In conclusion, our study has highlighted the widespread nature of cognitive impairment in PD. All of the cognitive domains examined except language function correlated positively with metabolism in posterior temporo-parieto-occipital cortex, suggesting a larger cortical involvement than the classic striato-frontal hypothesis. We propose that these findings indicate that the posterior cortical areas, encompassing multiple neurotransmitters and neural circuits, participate in the pathogenesis of cognitive decline in PD. The detailed neurobiological mechanisms remain to be clarified in future studies.
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